TITLE

GENERAL SAFETY OF MOXIFLOXACIN

AUTHOR(S)
Iannini, Paul B.
PUB. DATE
June 2002
SOURCE
Formulary;Jun2002 Supplement 3, Vol. 37 Issue 6, p32
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Assesses the general safety of moxifloxacin. Benefits of the metabolic and excretory characteristics of moxifloxacin; Drug reactions associated with quinolones; Effects of quinolones on cardiac tissues.
ACCESSION #
6864713

 

Related Articles

  • Pharmacokinetics and Tissue Penetration of Moxifloxacin in Intervention Therapy for Intra- Abdominal Abscess. Rink, Andreas D.; Stass, Heino; Delesen, Heinz; Kubitza, Dagmar; Vestweber, Karl-Heinz // Clinical Drug Investigation;2008, Vol. 28 Issue 2, p71 

    Background and objective: Intra-abdominal abscesses are usually polymicrobial and involve a variety of aerobic and anaerobic organisms. Thus, in addition to adequate drainage, empirical coverage with broad-spectrum antimicrobials is central to the management of such abscesses and an...

  • Effect of Febrile Condition and Ketoprofen Co-administration on Pharmacokinetics of Moxifloxacin Following Intravenous Administration in Sheep. Sadariya, K. A.; Patel, J. B.; Bhavsar, S. K.; Thaker, A. M. // Israel Journal of Veterinary Medicine;Jun2014, Vol. 69 Issue 2, p68 

    The present study was planned to determine the effect of intramuscularly administered ketoprofen (3 mg/kg) and lipopolysaccharide induced febrile condition on pharmacokinetics of moxifloxacin following intravenous administration (5 mg/kg) in sheep. Moxifloxacin was assayed in plasma by High...

  • Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration. Stass, H.; Kubitza, D.; Schühly, U. // Clinical Pharmacokinetics;2001 Supplement 1, Vol. 40 Issue 1, p1 

    Objective: To investigate the pharmacokinetics, safety and tolerability of moxifloxacin after single and repeated doses. Design and setting: This series comprised 3 separate placebo-controlled studies, 2 studies with a randomised crossover design (up to 400 mg/day) and 1 study with a group...

  • Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers. Stass, H.; Schuhly, U.; Möller, J-G.; Delesen, H. // Clinical Pharmacokinetics;2001 Supplement 1, Vol. 40 Issue 1, p49 

    Objective: To investigate the effect of concomitant Al (sucralfate) administration on the pharmacokinetics and tolerability of moxifloxacin. Design: This was a single-centre, randomised, nonblinded, 2-way crossover study in healthy volunteers. Participants: 12 healthy men (age 21 to 41 years)...

  • Ciprofloxacin/moxifloxacin.  // Reactions Weekly;2/13/2010, Issue 1288, p12 

    The article describes the case of a 48-year-old man who developed tendon rupture after receiving ciprofloxacin and moxifloxacin for recurrent episodes of otitis media (OM).

  • Moxifloxacin.  // Reactions Weekly;9/25/2010, Issue 1320, p35 

    The article describes the case of a 36-year-old man who developed an uveitis-like syndrome and iris depigmentation while receiving moxifloxacin for otitis.

  • Moxifloxacin.  // Reactions Weekly;10/20/2012, Issue 1424, p37 

    The article describes two cases of uveitis associated with the use of systemic moxifloxacin for acute sinusitis.

  • Moxifloxacin.  // Reactions Weekly;8/18/2012, Issue 1415, p36 

    The article describes the case of a 75-year-old woman who developed rhabdomyolysis while receiving moxifloxacin for a catheter-associated urinary tract infection (UTI).

  • Ketamine abuse.  // Reactions Weekly;7/7/2012, Issue 1409, p30 

    The article describes the case of a 24-year-old man who developed severe lower urinary tract symptoms (LUTS) after abusing ketamine and was treated with moxifloxacin.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics